2 Wall Street Analysts Think Argenx Can Soar More Than 40%. Here's Why They're Right.

Argenx posted 60% year-over-year Q2 2026 sales growth, 16% sequential revenue growth, and a 93% increase in earnings, extending its revenue-growth streak to 18 consecutive quarters. Wells Fargo and UBS each see more than 40% upside over the next 12 months, versus roughly 20% implied by the consensus target, supported by positive Phase 3 Alkivia data for Vyvgart Hytrulo in autoimmune myositis. Key risks are the company's complete dependence on the Vyvgart franchise and potential late-stage clinical setbacks for empraisprubart in multifocal motor neuropathy and CIDP.

Analysis

ARGX is transitioning from a single-indication rare-disease story into an FcRn-platform valuation, but the market will require evidence that new indications add durable treated-patient pools rather than merely expanding label optionality. The key earnings sensitivity over the next 1-3 quarters is net patient starts, persistence and gross-to-net trends for the subcutaneous formulation; modest deceleration in these metrics would matter more than headline revenue growth because the stock already embeds a premium probability of repeated indication expansion.

The late-stage autoimmune-myositis result raises the strategic value of the franchise but also increases concentration risk: virtually all enterprise value remains tied to one mechanism, one commercial organization and one reimbursement playbook. Competitors in FcRn inhibition, including UCB's Rystiggo (UCB.BR) and Johnson & Johnson's nipocalimab program (JNJ), could pressure duration, formulary access or net pricing even if the addressable market expands. A favorable label does not automatically translate to rapid revenue; diagnostic bottlenecks and specialist-channel capacity can delay uptake by several quarters.

Near term, bullish analyst targets are a weak standalone catalyst after a 30% twelve-month move; estimate revisions and commercial KPIs, not target-price reiterations, should determine direction. The more asymmetric event is the Q4 empasiprubart MMN readout: success creates a second meaningful asset and reduces franchise concentration, while failure likely compresses the pipeline multiple even if core Vyvgart execution remains intact. Contrarian view: the market may be underpricing the downside from a single disappointing quarterly patient-addition print, but also underpricing platform value if management demonstrates that subcutaneous conversion improves adherence and payer economics.

A risk-on biotech tape can sustain the premium for 6-18 months, but rate-driven multiple compression or an FcRn competitor securing superior access would overwhelm otherwise solid operating delivery. Falsify the constructive thesis if management guides to slowing net product sales, worsening gross-to-net, or materially weaker persistence; reassess the bearish case if new-indication launch metrics exceed base-case uptake within two quarters of approval.

Key Decisions for Investors

• Maintain a modest long ARGX only into the next earnings update if channel checks confirm stable patient starts and subcutaneous conversion; use a 10-12% position stop or exit on a clear sequential deterioration in net sales/persistence. Upside requires upward consensus revisions, not analyst target changes.
• For Q4 event exposure, prefer a defined-risk ARGX call spread dated after the MMN readout rather than outright stock: buy an at-the-money call and sell a 15-20% out-of-the-money call. This captures a positive readout while limiting premium paid for elevated binary-event volatility.
• Pair a long ARGX position with short XBI or IBB over the next 1-3 months for company-specific execution exposure while reducing biotech-beta and rates sensitivity. Close the hedge if ARGX patient metrics weaken, since the thesis then becomes idiosyncratically negative.
• Watch UCB.BR and JNJ FcRn clinical/commercial disclosures as competitive alerts rather than immediate shorts. Evidence of superior dosing convenience, efficacy, or payer-preferred placement would warrant trimming ARGX before its next guidance cycle.